Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

How do we improve patient compliance and adherence to long-term statin therapy?

Maningat P, Gordon BR, Breslow JL.

Curr Atheroscler Rep. 2013 Jan;15(1):291. doi: 10.1007/s11883-012-0291-7. Review.

2.

[Statins with a perspective of lifelong therapy].

ErtaƟ FS.

Turk Kardiyol Dern Ars. 2009 Mar;37 Suppl 2:29-36. Review. Turkish.

4.

Benefits of statin therapy and compliance in high risk cardiovascular patients.

Lardizabal JA, Deedwania PC.

Vasc Health Risk Manag. 2010 Oct 5;6:843-53. doi: 10.2147/VHRM.S9474. Review.

5.

Intensive statin therapy for Indians: Part-I. Benefits.

Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.

Indian Heart J. 2011 May-Jun;63(3):211-27. Review.

PMID:
22734339
6.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
7.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816. doi: 10.1002/14651858.CD004816.pub5. Review.

PMID:
23440795
8.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004816.

9.

Statins and the primary prevention of cardiovascular events.

Clearfield M.

Curr Atheroscler Rep. 2006 Sep;8(5):390-6. Review.

PMID:
16901409
10.

A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.

Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Review.

PMID:
23754124
11.

Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education.

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA.

J Clin Lipidol. 2013 Sep-Oct;7(5):472-83. doi: 10.1016/j.jacl.2013.03.001. Epub 2013 Mar 13.

PMID:
24079289
12.

Should every patient with diabetes receive a statin?

Dembowski E, Davidson MH.

Pol Arch Med Wewn. 2008 Jul-Aug;118(7-8):398-401. No abstract available.

13.
14.

Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy.

Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N.

Eur J Clin Pharmacol. 2008 Apr;64(4):425-32. doi: 10.1007/s00228-007-0428-8. Epub 2008 Jan 5.

PMID:
18176802
15.

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.

Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J.

BMJ. 2016 Jun 28;353:i3305. doi: 10.1136/bmj.i3305.

16.

Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.

Persell SD, Brown T, Lee JY, Shah S, Henley E, Long T, Luther S, Lloyd-Jones DM, Jean-Jacques M, Kandula NR, Sanchez T, Baker DW.

Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):560-6. doi: 10.1161/CIRCOUTCOMES.115.001723. Epub 2015 Nov 10.

17.

Being well-informed about statin is associated with continuous adherence and reaching targets.

Yilmaz MB, Pinar M, Naharci I, Demirkan B, Baysan O, Yokusoglu M, Erinc K, Tandogan I, Isik E.

Cardiovasc Drugs Ther. 2005 Dec;19(6):437-40.

PMID:
16435071
18.

Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk.

Perlmutter D, Golomb B, Sinatra S, Campbell AW.

Altern Ther Health Med. 2013;19 Suppl 1:14-25. No abstract available.

PMID:
23981463
19.

Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings.

Shalev V, Goldshtein I, Halpern Y, Chodick G.

Pharmacotherapy. 2014 Jan;34(1):1-8. doi: 10.1002/phar.1326. Epub 2013 Jul 8.

PMID:
23836549
20.

Does the benefit from statin therapy extend beyond 5 years?

Bulbulia R, Armitage J.

Curr Atheroscler Rep. 2013 Feb;15(2):297. doi: 10.1007/s11883-012-0297-1. Review.

PMID:
23299638

Supplemental Content

Support Center